A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT ID: NCT04968574

Last Updated: 2024-12-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-08-26
• Study Completion Date: 2023-11-30

Brief Summary

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

Conditions

Idiopathic Pulmonary Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

ENV-101

taladegib, 200 mg tablet, once daily for 12 weeks

Group Type: EXPERIMENTAL

taladegib

Intervention Type: DRUG

hedgehog pathway inhibitor dosed once daily

placebo

placebo, tablet, once daily for 12 weeks

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

identical tablets to the experimental arm with no active ingredient

Interventions

taladegib

hedgehog pathway inhibitor dosed once daily

Intervention Type: DRUG

placebo

identical tablets to the experimental arm with no active ingredient

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• IPF diagnosis based upon American Thoracic Association, Japanese Respiratory Society, European Respiratory Society, Latin American Thoracic Association guidelines within the last 7 years. Diagnosis will be confirmed to be consistent with IPF by centrally read high resolution computed tomography (HRCT).
• Ability to successfully perform lung function tests.
• Subjects are willing to remain on study treatment for the duration of the study.
• Subjects have a full understanding of the informed consent.

Exclusion Criteria

• Evidence of other known causes of interstitial lung disease (ILD) (e.g., domestic, and occupational environmental exposures, connective tissue disease [CTD], and drug toxicity), lung transplant expected within 12 months of screening or evidence of clinically significant lung disease other than IPF including but not limited to asthma, chronic obstructive pulmonary disease (COPD), uncontrolled pulmonary hypertension and emphysema where computed tomography (CT)-assessed extent of emphysema is greater than extent of fibrosis.
• History of malignancy, including carcinoma during the preceding 5 years. With the following exceptions:

1. Prior history of in situ basal or squamous cell skin cancer that was successfully treated with curative therapies.

2. Subjects with other malignancies if they have been continuously disease free for at least 5 years prior to study start.

3. Subjects with prostate cancer that are managed by surveillance are also eligible.

• Current use of supplemental oxygen for any condition unless prior approval is received from the Sponsor.
• Smoking within 6 months of study start, current smoker, or unwillingness to refrain from smoking during the clinical trial duration.
• Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV).
• Occurrence of serious illness requiring hospitalization within 90 days prior to study start.
• Current or previous use (within 30 days prior to study start) of the following:

1. N-acetylcysteine

2. endothelin receptor antagonist

3. riociguat

4. prostacyclin or prostacyclin analogue

5. Warfarin for IPF

6. Cytotoxic agents (e.g., colchicine if used for IPF)

7. Radiation to the lungs

8. Pulmonary rehabilitation

9. Investigational agent for IPF

10. Immunosuppressive medications (e.g., methotrexate, azathioprine)

11. Systemic or inhaled glucocorticosteroids

12. Antifibrotic therapy (e.g., nintedanib, pirfenidone)

• Regular use of phosphodiesterase type-5 inhibitor, occasional use for erectile dysfunction will be allowed.
• Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 12 days prior to study start.
• Males and females of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 3 months after their final dose.
• Females that are pregnant or nursing.
• Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose.
• Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final study dose.
• Subjects with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of ENV-101.
• Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Endeavor Biomedicines, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

John Huetsch, M.D.

Role: STUDY_DIRECTOR

Endeavor Biomedicines

Locations

Research Site

Liverpool, New South Wales, Australia

Research Site

Benowa, Queensland, Australia

Research Site

Box Hill, Victoria, Australia

Research Site

Clayton, Victoria, Australia

Research Site

Vancouver, British Columbia, Canada

Research Site

Sherbrooke, Quebec, Canada

Research Site

Batu Caves, , Malaysia

Research Site

Kota Bharu, , Malaysia

Research Site

Kuala Lumpur, , Malaysia

Research Sire

Kuala Lumpur, , Malaysia

Research Site

Kuala Lumpur, , Malaysia

Research Site

Monterrey, Nuevo León, Mexico

Research Site

Monterrey, Nuevo León, Mexico

Research Site

San Nicolás de los Garza, Nuevo León, Mexico

Research Site

Chihuahua City, , Mexico

Research Site

Mexico City, , Mexico

Research Site

Mexico City, , Mexico

Research Site

Oaxaca City, , Mexico

Research Site

Puebla City, , Mexico

Research Site (Namdong District)

Incheon, , South Korea

Research Site (Bundang District)

Seongnam, , South Korea

Research Site (Gangnam District)

Seoul, , South Korea

Research Site (Seongbuk District)

Seoul, , South Korea

Research Site (Songpa District)

Seoul, , South Korea

Countries

Australia; Canada; Malaysia; Mexico; South Korea

References

Maher TM, Goldin JG, Hood J, Pitman J, de Los Rios M, Hobbs BP, Yu-Lin AB, Buendia-Roldan I, Thien F, Song JW, Perea PC, Ramirez-Rivera A, DiFrancesco A. Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025 Sep 30:S2213-2600(25)00239-5. doi: 10.1016/S2213-2600(25)00239-5. Online ahead of print.

Reference Type: DERIVED

PMID: 41043447 (View on PubMed)

Other Identifiers

ENV-IPF-101

Identifier Type: -

Identifier Source: org_study_id